Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes.
Fifty-three patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes were treated with radiation therapy (median, 70 Gy), cisplatin (median, 6 weekly courses) and hyperthermia (median, 6 twice weekly sessions). Local complete response was achieved in 82% and nodal complete response in 85% of patients. Overall survival was 51% and disease-free survival was 54% at 2 years. Toxicity was acceptable. Radiation therapy, cisplatin and hyperthermia in combination prove to be effective and safe in management of these patients.
Serin
M
M
Department of Radiation Oncology, Ankara University Faculty of Medicine, Dikimevi, Turkey.
Erkal
H S
HS
Cakmak
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003037:Cobalt Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000628:therapy; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D008207:Lymphatic Metastasis / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009333:Neck; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012074:Remission Induction; D015996:Survival Rate
D000970:Antineoplastic Agents; D003037:Cobalt Radioisotopes; D019275:Radiopharmaceuticals; D002945:Cisplatin